Alector reports Q4 EPS (34c), consensus (36c)

Reports Q4 revenue $6.2M, consensus $1.96M. “Alector’s (ALEC) strength lies in the combination of a highly differentiated blood-brain barrier platform and a team with deep experience executing complex neurodegenerative programs,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “Following more than six years of focused investment in our ABC technology, we believe the breadth, flexibility, and tunability of our ABC platform position us to translate scientific innovation into exciting clinical-stage assets. At the same time, we continue to advance the PROGRESS-AD Phase 2 trial of nivisnebart in early Alzheimer’s disease, together with GSK, toward an independent interim futility analysis in the first half of 2026.”